Skip to content

Multicenter Clinical Study of Dentate Nucleus Deep Brain Stimulation for Treating Post-Stroke Movement Disorders

Clinical Study on Deep Brain Stimulation of the Cerebellar Dentate Nucleus for Post-Stroke Movement Disorders

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103501
Enrollment
Unknown
Registered
2025-05-30
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent moderate to severe upper limb hemiplegia

Interventions

Surgical group:DN-DBS

Sponsors

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years 2. confirmed diagnosis of stroke (ischemic or hemorrhagic) within 12-36 months 3. persistent moderate to severe upper limb hemiplegia, defined as Fugl-Meyer Assessment of Upper Extremity (FMA-UE) score =1 for elbow flexion, elbow extension, or finger flexion/extension) 4. preserved standard physiological motor pathway response, evidenced by motor evoked potential (MEP) peak-to-peak amplitude >=100µV in partially contracted extensor digitorum communis or proximal muscles (including forearm or wrist flexors) 5. ability of the subject or their legal guardian to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe spasticity or contracture of upper limb muscles 2. diagnosed neurological/psychiatric disorders (e.g., Alzheimer's disease, amyotrophic lateral sclerosis [ALS], Parkinson's disease) 3. contraindications to neurosurgical procedures 4. contraindications to CT/MRI scanning (e.g., claustrophobia) 5. female subjects with known pregnancy, lactation, or positive pregnancy test prior to randomization 6. contraindications to general anesthesia (e.g., severe arrhythmia, severe anemia, abnormal hepatic/renal function) 7. life expectancy <12 months.

Design outcomes

Primary

MeasureTime frame
Limb muscle strength and tone;Fugl-Meyer Assessment (FMA) score;Modified Ashworth Scale (MAS);somatosensory evoked potentials (SSEPs), motor evoked potentials (MEPs).;brain function;

Countries

China

Contacts

Public ContactNiu Chaoshi

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science

niuchaoshi@163.com+86 138 5518 6208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026